Outcome of Botulinum Toxin‐A intraprostatic injection for benign prostatic hyperplasia induced lower urinary tract symptoms: A prospective multicenter study

Introduction Our aim was to determine the factors predicting the outcome of intraprostatic injection of Botulinum Toxin‐A (BTX‐A) in the treatment of benign prostatic hyperplasia (BPH)‐induced lower urinary tract symptoms (LUTS) and to evaluate its efficacy and safety. Methods Between September 2016...

Full description

Saved in:
Bibliographic Details
Published in:The Prostate 2019-08, Vol.79 (11), p.1221-1225
Main Authors: Moussa, Ayman S., Ragheb, Ahmed M., Abdelbary, Ahmed M., Ibrahim, Rabie M., El Adawy, Mahmoud S., Aref, Ahmad, Assem, Ahmed, Elfayoumy, Hany, Elzawy, Faysal
Format: Article
Language:English
Subjects:
Aged
Benign
benign prostatic hyperplasia
botox
Botulinum toxin
Botulinum Toxins, Type A - administration & dosage
Botulinum Toxins, Type A - therapeutic use
Genital diseases
Humans
Hyperplasia
Injection
lower urinary tract symptoms
Lower Urinary Tract Symptoms - drug therapy
Lower Urinary Tract Symptoms - etiology
Male
Middle Aged
Patients
Prospective Studies
Prostate
Prostate - drug effects
Prostatic Hyperplasia - complications
Quality of Life
Treatment Outcome
Urinary tract
Urine
Urogenital system
Urological Agents - administration & dosage
Urological Agents - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Our aim was to determine the factors predicting the outcome of intraprostatic injection of Botulinum Toxin‐A (BTX‐A) in the treatment of benign prostatic hyperplasia (BPH)‐induced lower urinary tract symptoms (LUTS) and to evaluate its efficacy and safety. Methods Between September 2016 and May 2018, 45 Egyptian patients, with BPH‐induced LUTS were included; the indication was a failure of medical treatment, unfit, or refusing surgical intervention. Measurements of prostate size by TRUS, total PSA level before and 12 weeks after injection. IPSS, uroflow, and postvoiding residual urine (PVR) were measured before injection, 2, 4, 8 and 12 weeks postinjection. 100 U BTX‐A vial was diluted with 10 mL of saline then injected into the transition zone at base and midzone of the prostate by TRUS. Results The mean patients' age was 64.4 ± 6.6 years. Mean baseline IPSS 24.06 decreased to 18.75 at 2 weeks and progressively decreased to 16.37 at 12 weeks (P 
ISSN:0270-4137
1097-0045
DOI:10.1002/pros.23805